Cargando…

Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study

INTRODUCTION: Social disruption associated with coronavirus disease 2019 (COVID‐19) threatens to impede access to regular healthcare, including for people living with HIV (PLHIV), potentially resulting in antiretroviral therapy (ART) interruption (ATI). We aimed to explore the characteristics and fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yinghui, Li, Hui, Luo, Ganfeng, Meng, Xiaojun, Guo, Wei, Fitzpatrick, Thomas, Ao, Yunlong, Feng, Anping, Liang, Bowen, Zhan, Yuewei, Sande, Amakobe, Xie, Feng, Wang, Ying, Qian, Han‐Zhu, Cai, Yong, Zou, Huachun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645858/
https://www.ncbi.nlm.nih.gov/pubmed/33247541
http://dx.doi.org/10.1002/jia2.25637
_version_ 1783606708041416704
author Sun, Yinghui
Li, Hui
Luo, Ganfeng
Meng, Xiaojun
Guo, Wei
Fitzpatrick, Thomas
Ao, Yunlong
Feng, Anping
Liang, Bowen
Zhan, Yuewei
Sande, Amakobe
Xie, Feng
Wang, Ying
Qian, Han‐Zhu
Cai, Yong
Zou, Huachun
author_facet Sun, Yinghui
Li, Hui
Luo, Ganfeng
Meng, Xiaojun
Guo, Wei
Fitzpatrick, Thomas
Ao, Yunlong
Feng, Anping
Liang, Bowen
Zhan, Yuewei
Sande, Amakobe
Xie, Feng
Wang, Ying
Qian, Han‐Zhu
Cai, Yong
Zou, Huachun
author_sort Sun, Yinghui
collection PubMed
description INTRODUCTION: Social disruption associated with coronavirus disease 2019 (COVID‐19) threatens to impede access to regular healthcare, including for people living with HIV (PLHIV), potentially resulting in antiretroviral therapy (ART) interruption (ATI). We aimed to explore the characteristics and factors associated with ATI during the COVID‐19 outbreak in China. METHODS: We conducted an online survey among PLHIV by convenience sampling through social media between 5 and 17 February 2020. Respondents were asked to report whether they were at risk of ATI (i.e. experienced ATI, risk of imminent ATI, threatened but resolved risk of ATI [obtaining ART prior to interruption]) or were not at risk of ATI associated with the COVID‐19 outbreak. PLHIV were also asked to report perceived risk factors for ATI and sources of additional ART. The factors associated with the risk of ATI were assessed using logistic regression. We also evaluated the factors associated with experienced ATI. RESULTS: A total of 5084 PLHIV from 31 provinces, autonomous regions and municipalities in mainland China completed the survey, with valid response rate of 99.4%. The median age was 31 years (IQR 27 to 37), 96.5% of participants were men, and 71.3% were men who had sex with men. Over one‐third (35.1%, 1782/5084) reported any risk of ATI during the COVID‐19 outbreak, including 2.7% (135/5084) who experienced ATI, 18.0% (917/5084) at risk of imminent ATI and 14.4% (730/5084) at threatened but resolved risk. PLHIV with ATI were more likely to have previous interruptions in ART (aOR 8.3, 95% CI 5.6 to 12.3), travelled away from where they typically receive HIV care (aOR 3.0, 95% CI 2.1 to 4.5), stayed in an area that implemented citywide lockdowns or travel restrictions to control COVID‐19 (aOR 2.5, 95% CI 1.4 to 4.6), and be in permanent residence in a rural area (aOR 3.7, 95% CI 2.3 to 5.8). CONCLUSIONS: A significant proportion of PLHIV in China are at risk of ATI during the COVID‐19 outbreak and some have already experienced ATI. Correlates of ATI and self‐reported barriers to ART suggest that social disruptions from COVID‐19 have contributed to ATI. Our findings demonstrate an urgent need for policies and interventions to maintain access to HIV care during public health emergencies.
format Online
Article
Text
id pubmed-7645858
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76458582020-11-06 Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study Sun, Yinghui Li, Hui Luo, Ganfeng Meng, Xiaojun Guo, Wei Fitzpatrick, Thomas Ao, Yunlong Feng, Anping Liang, Bowen Zhan, Yuewei Sande, Amakobe Xie, Feng Wang, Ying Qian, Han‐Zhu Cai, Yong Zou, Huachun J Int AIDS Soc Research Articles INTRODUCTION: Social disruption associated with coronavirus disease 2019 (COVID‐19) threatens to impede access to regular healthcare, including for people living with HIV (PLHIV), potentially resulting in antiretroviral therapy (ART) interruption (ATI). We aimed to explore the characteristics and factors associated with ATI during the COVID‐19 outbreak in China. METHODS: We conducted an online survey among PLHIV by convenience sampling through social media between 5 and 17 February 2020. Respondents were asked to report whether they were at risk of ATI (i.e. experienced ATI, risk of imminent ATI, threatened but resolved risk of ATI [obtaining ART prior to interruption]) or were not at risk of ATI associated with the COVID‐19 outbreak. PLHIV were also asked to report perceived risk factors for ATI and sources of additional ART. The factors associated with the risk of ATI were assessed using logistic regression. We also evaluated the factors associated with experienced ATI. RESULTS: A total of 5084 PLHIV from 31 provinces, autonomous regions and municipalities in mainland China completed the survey, with valid response rate of 99.4%. The median age was 31 years (IQR 27 to 37), 96.5% of participants were men, and 71.3% were men who had sex with men. Over one‐third (35.1%, 1782/5084) reported any risk of ATI during the COVID‐19 outbreak, including 2.7% (135/5084) who experienced ATI, 18.0% (917/5084) at risk of imminent ATI and 14.4% (730/5084) at threatened but resolved risk. PLHIV with ATI were more likely to have previous interruptions in ART (aOR 8.3, 95% CI 5.6 to 12.3), travelled away from where they typically receive HIV care (aOR 3.0, 95% CI 2.1 to 4.5), stayed in an area that implemented citywide lockdowns or travel restrictions to control COVID‐19 (aOR 2.5, 95% CI 1.4 to 4.6), and be in permanent residence in a rural area (aOR 3.7, 95% CI 2.3 to 5.8). CONCLUSIONS: A significant proportion of PLHIV in China are at risk of ATI during the COVID‐19 outbreak and some have already experienced ATI. Correlates of ATI and self‐reported barriers to ART suggest that social disruptions from COVID‐19 have contributed to ATI. Our findings demonstrate an urgent need for policies and interventions to maintain access to HIV care during public health emergencies. John Wiley and Sons Inc. 2020-11-01 /pmc/articles/PMC7645858/ /pubmed/33247541 http://dx.doi.org/10.1002/jia2.25637 Text en © 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Sun, Yinghui
Li, Hui
Luo, Ganfeng
Meng, Xiaojun
Guo, Wei
Fitzpatrick, Thomas
Ao, Yunlong
Feng, Anping
Liang, Bowen
Zhan, Yuewei
Sande, Amakobe
Xie, Feng
Wang, Ying
Qian, Han‐Zhu
Cai, Yong
Zou, Huachun
Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title_full Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title_fullStr Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title_full_unstemmed Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title_short Antiretroviral treatment interruption among people living with HIV during COVID‐19 outbreak in China: a nationwide cross‐sectional study
title_sort antiretroviral treatment interruption among people living with hiv during covid‐19 outbreak in china: a nationwide cross‐sectional study
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645858/
https://www.ncbi.nlm.nih.gov/pubmed/33247541
http://dx.doi.org/10.1002/jia2.25637
work_keys_str_mv AT sunyinghui antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT lihui antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT luoganfeng antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT mengxiaojun antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT guowei antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT fitzpatrickthomas antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT aoyunlong antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT fenganping antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT liangbowen antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT zhanyuewei antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT sandeamakobe antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT xiefeng antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT wangying antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT qianhanzhu antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT caiyong antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy
AT zouhuachun antiretroviraltreatmentinterruptionamongpeoplelivingwithhivduringcovid19outbreakinchinaanationwidecrosssectionalstudy